Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 28Gynecologic 2Gastrointestinal 2Thoracic 1Other solid neoplasm 1Head & Neck 1CNS 1

Conditions

Ovarian Neoplasms 2

Interventions

Paclitaxel 233Carboplatin 217Bevacizumab 139Cisplatin 134pembrolizumab 89Gemcitabine 69olaparib 54Docetaxel 47Topotecan 44Radiotherapy 43liposomal doxorubicin 41Taxes 41niraparib 38Cyclophosphamide 36Doxorubicin 30Letrozole 28Drug Therapy 28Nivolumab 27Magnetic Resonance Spectroscopy 25Immunoglobulin G 25Disulfides 24Oxaliplatin 23durvalumab 22Albumin-Bound Paclitaxel 22apatinib 21Etoposide 21Brachytherapy 21lenvatinib 20Specimen Handling 20Filgrastim 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × dalpiciclib × Gynecologic × Clear all
NCT06552858 2024-08-14

Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer

Fudan University

Phase 2 Not yet recruiting
30 enrolled
Gynecologic

Ovarian Neoplasms

NCT06243185 2024-02-06

Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid Tumors

Peking Union Medical College Hospital

Phase 2 Unknown
30 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡